Creo Medical has announced it has received 510(k) clearance from the FDA for the second product in its MicroBlate range of soft tissue ablation devices, MicroBlate Flex. This follows the US clearance of the MicroBlate Fine device in November 2020 and represents Creo's third US clearance in the past 12 months and the company's fourth US clearance in total. The MicroBlate Flex has been designed to ablate nodules and tumours in tissue locations where flexibility and a small diameter are required to ....
07 Jan 2021
Cenkos: Creo Medical Group Plc -- FDA clearance for MicroBlate Flex
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc -- FDA clearance for MicroBlate Flex
Creo Medical Group Plc (CREO:LON) | 34.2 -0.2 (-1.4%) | Mkt Cap: 123.8m
- Published:
07 Jan 2021 -
Author:
Chris Donnellan -
Pages:
5
Creo Medical has announced it has received 510(k) clearance from the FDA for the second product in its MicroBlate range of soft tissue ablation devices, MicroBlate Flex. This follows the US clearance of the MicroBlate Fine device in November 2020 and represents Creo's third US clearance in the past 12 months and the company's fourth US clearance in total. The MicroBlate Flex has been designed to ablate nodules and tumours in tissue locations where flexibility and a small diameter are required to ....